TY - JOUR
T1 - Protein and peptide delivery to lungs by using advanced targeted drug delivery
AU - Chellappan, Dinesh Kumar
AU - Prasher, Parteek
AU - Saravanan, Vilashini
AU - Vern Yee, Vanessa See
AU - Wen Chi, Wendy Chai
AU - Wong, Jia Wei
AU - Wong, Joon Kang
AU - Wong, Jing Tong
AU - Wan, Wai
AU - Chellian, Jestin
AU - Molugulu, Nagashekhara
AU - Prabu, Sakthivel Lakshmana
AU - Ibrahim, Rania
AU - Darmarajan, Thiviya
AU - Candasamy, Mayuren
AU - Singh, Pankaj Kumar
AU - Mishra, Vijay
AU - Shastri, Madhur D.
AU - Zacconi, Flavia C.
AU - Chakraborty, Amlan
AU - Mehta, Meenu
AU - Gupta, Piyush Kumar
AU - Dureja, Harish
AU - Gulati, Monica
AU - Singh, Sachin Kumar
AU - Gupta, Gaurav
AU - Jha, Niraj Kumar
AU - George Oliver, Brian Gregory
AU - Dua, Kamal
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2022/1/5
Y1 - 2022/1/5
N2 - The challenges and difficulties associated with conventional drug delivery systems have led to the emergence of novel, advanced targeted drug delivery systems. Therapeutic drug delivery of proteins and peptides to the lungs is complicated owing to the large size and polar characteristics of the latter. Nevertheless, the pulmonary route has attracted great interest today among formulation scientists, as it has evolved into one of the important targeted drug delivery platforms for the delivery of peptides, and related compounds effectively to the lungs, primarily for the management and treatment of chronic lung diseases. In this review, we have discussed and summarized the current scenario and recent developments in targeted delivery of proteins and peptide-based drugs to the lungs. Moreover, we have also highlighted the advantages of pulmonary drug delivery over conventional drug delivery approaches for peptide-based drugs, in terms of efficacy, retention time and other important pharmacokinetic parameters. The review also highlights the future perspectives and the impact of targeted drug delivery on peptide-based drugs in the coming decade.
AB - The challenges and difficulties associated with conventional drug delivery systems have led to the emergence of novel, advanced targeted drug delivery systems. Therapeutic drug delivery of proteins and peptides to the lungs is complicated owing to the large size and polar characteristics of the latter. Nevertheless, the pulmonary route has attracted great interest today among formulation scientists, as it has evolved into one of the important targeted drug delivery platforms for the delivery of peptides, and related compounds effectively to the lungs, primarily for the management and treatment of chronic lung diseases. In this review, we have discussed and summarized the current scenario and recent developments in targeted delivery of proteins and peptide-based drugs to the lungs. Moreover, we have also highlighted the advantages of pulmonary drug delivery over conventional drug delivery approaches for peptide-based drugs, in terms of efficacy, retention time and other important pharmacokinetic parameters. The review also highlights the future perspectives and the impact of targeted drug delivery on peptide-based drugs in the coming decade.
KW - Administration, Inhalation
KW - Animals
KW - Drug Carriers/administration & dosage
KW - Humans
KW - Lung Diseases/drug therapy
KW - Lung/drug effects
KW - Nanoparticles/administration & dosage
KW - Peptides/administration & dosage
KW - Proteins/administration & dosage
U2 - 10.1016/j.cbi.2021.109706
DO - 10.1016/j.cbi.2021.109706
M3 - Article
C2 - 34662570
AN - SCOPUS:85118509258
SN - 0009-2797
VL - 351
JO - Chemico-Biological Interactions
JF - Chemico-Biological Interactions
M1 - 109706
ER -
